UCLA researchers confirm mutations that predispose patients to rare kidney cancer syndrome

FHS
July 13, 2023
4:35 am

Researchers at the UCLA Jonsson Comprehensive Cancer Center have confirmed that a large number of genetic variants of unknown significance are in fact verified mutations that predispose patients to a rare hereditary syndrome that increases the risk of kidney cancer.

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 26, 2024

Future drug makers can develop their skills using virtual reality at new national Centre of Excellence

Future medicine and vaccine makers will be able to develop their skills using virtual reality at a new national Centre of Excellence, after a successful

March 15, 2024

What Does the Evidence Say About Immunotherapy Rechallenge in RCC?

Treatment of metastatic renal cell carcinoma (RCC) continues to rapidly evolve, with various combinations of immune checkpoint inhibitors (ICIs) and targeted tyrosine kinase inhibitors improving

June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.